CalciMedica (NASDAQ:CALC) Director Fred Middleton Buys 248,972 Shares of Stock

CalciMedica Inc. (NASDAQ:CALC) Director Fred Middleton bought 248,972 shares of the stock in a transaction dated Thursday, June 25th. The stock was purchased at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the purchase, the director directly owned 1,063,272 shares in the company, valued at approximately $850,617.60. This trade represents a 30.57% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

CalciMedica Stock Up 21.0%

CALC stock opened at $0.99 on Tuesday. CalciMedica Inc. has a twelve month low of $0.46 and a twelve month high of $7.20. The company has a market cap of $15.59 million, a P/E ratio of -0.75 and a beta of 0.97. The business has a fifty day moving average of $0.73 and a 200-day moving average of $1.90.

Analysts Set New Price Targets

Separately, Oppenheimer cut their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research report on Thursday, March 5th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CALC. Cetera Investment Advisers grew its stake in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the period. 180 Wealth Advisors LLC boosted its holdings in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after buying an additional 94,650 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the period. Jane Street Group LLC bought a new stake in shares of CalciMedica in the 4th quarter valued at about $127,000. Finally, Envestnet Asset Management Inc. increased its stake in shares of CalciMedica by 58.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after acquiring an additional 34,386 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.